(Q57485821)

English

Luseogliflozin: First Global Approval

article by Anthony Markham & Shelley Elkinson published 22 May 2014 in Drugs

In more languages

edit

Statements

instance of

scholarly article

0 references

title

Luseogliflozin: First Global Approval (English)

0 references

author name string

Anthony Markham

series ordinal

1

0 references

Shelley Elkinson

series ordinal

2

0 references

publication date

22 May 2014

0 references

published in

Drugs

0 references

volume

74

0 references

issue

8

0 references

page(s)

945-950

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s40265-014-0230-8

0 references

cites work

Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-014-0230-8

retrieved

21 January 2018

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-014-0230-8

retrieved

21 January 2018

(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-014-0230-8

retrieved

21 January 2018

TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-014-0230-8

retrieved

21 January 2018

Lack of TRPM2 impaired insulin secretion and glucose metabolisms in mice

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-014-0230-8

retrieved

21 January 2018

Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-014-0230-8

retrieved

21 January 2018

Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/24848756

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/24848756

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S40265-014-0230-8

0 references

PubMed ID

24848756

0 references

(Q57485821)

Luseogliflozin: First Global Approval

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)